January 08, 2018
Cancer-drug maker Seattle Genetics Inc. on Friday asked a Washington federal court for a third time to dismiss a proposed securities fraud class action against it, saying the latest complaint still doesn't spell out how it supposedly knew it was engaged in wrongdoing.
October 19, 2017
A Washington federal judge on Wednesday tossed a shareholder suit claiming a biotechnology company misled investors about the viability of its new leukemia treatment and concealed concerns the drug causes liver damage, finding the investors hadn't sufficiently alleged the company intended to mislead them, but left the door open for them to amend their complaint.
January 11, 2017
A cancer therapy developer led shareholders to believe testing for its new leukemia treatment drug was going smoothly despite the U.S. Food and Drug Administration's concerns that the drug causes liver damage, leading to decreased share values, a putative class alleged in Washington federal court Tuesday.